Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Rhea-AI Summary

Teva (NYSE:TEVA) reported new IMPACT-TD Registry data on adults with mood disorders and tardive dyskinesia (TD). Among young adults 18-29 (n=13), 85% had moderate to severe TD impact, yet only 23% were formally diagnosed, highlighting diagnostic gaps.

The 3-year, Phase 4, real-world registry includes 611 adults with TD; this analysis covered 211 with mood disorders not on VMAT2 inhibitors. Adults under 60 showed pronounced psychological effects, and patients waited on average over 3.5 years from first involuntary movements to TD diagnosis.

News Market Reaction – TEVA

-0.76%

-0.76% Session close to close

In the May 18 session, TEVA declined 0.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights substantial underdiagnosis and high burden of tardive dyskinesia in adu...

Analysis

This announcement highlights substantial underdiagnosis and high burden of tardive dyskinesia in adults with mood disorders, with 85% of young adults reporting moderate–severe impact but only 23% formally diagnosed. It underscores TEVA’s ongoing focus on neuroscience and real-world evidence, complementing recent earnings strength and pipeline advances. Investors may watch how such data inform clinical practice, potential label or guideline discussions, and utilization trends for TD therapies across different age and mood-disorder subgroups.

Key Figures

Young adult TD impact: 85% Young adult TD diagnosis: 23% IMPACT-TD participants: 611 participants +5 more

8 metrics

Young adult TD impact 85% Young adults aged 18–29 with TD movements (n=13) reporting moderate–severe impact

Young adult TD diagnosis 23% Ages 18–29 with TD movements formally diagnosed with tardive dyskinesia

IMPACT-TD participants 611 participants Adults ≥18 years enrolled in 3-year IMPACT-TD Registry

Mood disorder cohort 211 adults TD patients with concomitant mood disorders not on VMAT2 therapy

Bipolar prevalence 60% Proportion of analyzed TD patients with bipolar disorder

Depression prevalence 54% Proportion of analyzed TD patients with depression

Diagnosis rate age 40–49 57% Formal TD diagnosis rate among adults aged 40–49 (n=37)

Diagnosis delay More than 3.5 years Average wait from movement recognition to formal TD diagnosis

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Conference appearance	Positive	+1.4%	BofA health care conference presentation by Teva’s R&D leadership.
Apr 30	ESG/sustainability update	Positive	-0.9%	Healthy Future Report highlighting ESG progress and bond target achievements.
Apr 29	Product sales update	Positive	+11.9%	Strong UZEDY Q1 2026 U.S. net sales growth and regulatory milestones.
Apr 29	Earnings release	Positive	+11.9%	Q1 2026 results with innovative portfolio growth and maintained outlook.
Apr 29	Acquisition announcement	Positive	+11.9%	Agreement to acquire Emalex, adding an NDA-ready neuroscience therapy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive updates (earnings, pipeline, acquisition) often coincided with strong positive price moves, while ESG/sustainability news saw a mild negative reaction.

Recent Company History

Over the past few weeks, TEVA released several notable updates. On Apr 29, strong Q1 2026 results and growth in innovative brands coincided with an 11.89% gain, alongside news of acquiring Emalex and UZEDY sales strength. A sustainability report on Apr 30 with progress on bond targets and access initiatives saw a modest -0.88% move. A BofA conference appearance on May 04 was followed by a smaller 1.44% increase. Today’s TD registry data fits the broader neuroscience and patient-impact narrative.

Key Terms

tardive dyskinesia, mood disorders, phase 4, abnormal involuntary movement scale (aims), +2 more

6 terms

tardive dyskinesia medical

"confirms tardive dyskinesia (TD) causes a significant burden for most individuals"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

mood disorders medical

"tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders"

Mood disorders are a group of mental health conditions that cause long-lasting changes in a person’s emotional state—such as persistent low mood or dramatic swings between low and high energy—that affect thinking, sleep, appetite and daily functioning. Investors track them because they drive demand for medications, therapies and medical devices, influence clinical trial activity and regulatory reviews, and can affect workforce productivity and healthcare costs; think of them like a building’s thermostat stuck too high or low, with wide ripple effects across the healthcare and business landscape.

phase 4 medical

"a 3-year, prospective, non-interventional, Phase 4 study examining how TD progresses"

Phase 4 is the stage after a drug or vaccine has been approved and is sold to the public, where regulators and companies keep watching how it performs in the real world to detect rare side effects, long‑term effects, or differences in effectiveness across different groups. Think of it as ongoing quality control for a product already on shelves; results can prompt label changes, safety warnings, sales impacts or recalls, all of which matter to investors evaluating risk and future revenue.

abnormal involuntary movement scale (aims) medical

"had either a score of ≥2 on at least one item of the Abnormal Involuntary Movement Scale (AIMS)"

AIMS is a standardized clinical rating scale doctors use to track involuntary muscle movements, often caused by certain psychiatric or neurological drugs; think of it as a thermometer for uncontrollable facial and body motions. For investors, AIMS scores matter because rising or persistent scores can signal drug safety problems, affect clinical trial outcomes, regulatory reviews and labeling, and ultimately influence a company’s product value and stock outlook.

vesicular monoamine transporter 2 (vmat2) inhibitor medical

"or were receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy for TD"

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that reduces the storage and release of certain brain chemicals—like dopamine—by blocking the cellular 'pump' that loads them into storage vesicles. For investors, VMAT2 inhibitors matter because they can treat movement and psychiatric disorders, so clinical trial results, safety issues, and regulatory approval directly affect a drug maker’s future revenue and risk profile—think of it as turning down a faucet that controls signaling in the brain.

non-interventional medical

"is a 3-year, prospective, non-interventional, Phase 4 study examining how TD progresses"

A non-interventional study is a type of medical or regulatory study where researchers observe patients receiving routine care without assigning treatments or changing clinical decisions. For investors, these studies usually cost less and run faster than trials that test new drugs or devices, but their observational nature makes the evidence less definitive for regulatory approval or market-changing claims—think of watching passengers on a bus rather than changing the route to see the effect.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of age
• The data shows that 85% of young adults with mood disorders living with TD movements, ages 18-29 (n=13), experience moderate to severe TD impact, yet only 23% received a formal diagnosis of TD, revealing a gap in disease identification
• Teva is dedicated to advancing research and initiatives that deepen clinical understanding, identify diagnostic gaps and improve outcomes for patients with TD
  
  

PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.

“The latest data from the IMPACT-TD Registry underscores the profound, multidimensional impact of tardive dyskinesia on individuals, extending far beyond any single demographic. Despite its widespread impact, we are still confronted with meaningful diagnostic gaps, leaving many patients undiagnosed and untreated,” said Verena Ramirez Campos, MD-MBA, Vice President U.S. Medical Affairs and Global Innovative Strategy at Teva. “We are committed to grasping the complete human experience of TD, and working to help close those gaps and bring forth innovations that make a meaningful difference in the day-to-day lives of people living with TD.”

The IMPACT-TD Registry, the largest TD study to date, is a 3-year, prospective, non-interventional, Phase 4 study examining how TD progresses over time and the impact it has on patients’ lives.^1-3 The study, which includes a broad representation of people affected by TD (age, sex, race/ethnicity, underlying conditions, movement severity and treatment status), evaluates 611 participants aged ≥18 years who, at enrollment, had either a score of ≥2 on at least one item of the Abnormal Involuntary Movement Scale (AIMS) and probable TD, or were receiving vesicular monoamine transporter 2 (VMAT2) inhibitor therapy for TD. The present analysis of the IMPACT-TD Registry evaluated 211 adults with TD who were not receiving VMAT2 inhibitor therapy at enrollment and had concomitant mood disorders, such as bipolar disorder (60%) or depression (54%), reflecting a diverse, real-world patient population. Multidimensional impact of TD was measured using the clinician-reported IMPACT-TD scale, while TD severity was assessed by AIMS.

The IMPACT-TD findings revealed:

• A majority of participants, regardless of age, reported a moderate to severe global impact from TD. This burden was particularly high for those aged 18-29 (85%) and 50-59 (87%, n=57), demonstrating that TD significantly affects daily life across the adult lifespan.
• The psychological impact of TD was most pronounced in adults aged <60. Over three-quarters (77%) of those aged 18-29 experienced moderate to severe psychological effects despite lower AIMS scores (6.4) on average compared to older adults aged 60-69 (8.4, n=56) and >69 (9.9, n=28).
• Despite the high impact, formal TD diagnosis rates were lowest among adults <40 years old. The rate was 23% for participants aged 18-29 and 35% for participants aged 30-39 (n=20), well below the peak of 57% seen in adults aged 40-49 (n=37) and 47% average in the 50+ age subgroups.
• A significant delay in diagnosis was also identified, with patients waiting an average of more than 3.5 years to be formally diagnosed after their involuntary movements were first recognized.
  
  

“Beyond the visible symptoms, tardive dyskinesia impacts every aspect of daily living, from personal independence to social interaction and emotional wellbeing,” said Richard Jackson, MD, an Assistant Clinical Adjunct Professor in the University of Michigan School of Medicine’s Department of Psychiatry and IMPACT-TD principal investigator. “What remains a critical unknown is how this debilitating condition uniquely impacts those already struggling with mood disorders, especially at different ages. The IMPACT-TD study is designed to bridge this crucial knowledge gap, giving us the insights we urgently need to offer targeted, meaningful support to every TD patient, no matter their background.”

Teva is committed to assisting in addressing these significant diagnostic gaps, which could improve the lives of those living with tardive dyskinesia.

About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.^4-6

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully continue to develop and commercialize products for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease, and to improve the lives of those living with tardive dyskinesia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

1. Finkbeiner S, Konings M, Henegar M, et al. Multidimensional impact of tardive dyskinesia: interim analysis of clinician-reported measures in the IMPACT-TD registry. Poster presented at: Annual Psych Congress Elevate; May 30-June 2, 2024; Las Vegas, NV.
2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association; 2021.
4. Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258.
5. Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.
6. Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2023.

Teva Media Inquiries	TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries	TevaIR@Tevapharm.com

FAQ

What did Teva (NYSE:TEVA) announce about the IMPACT-TD Registry on May 18, 2026?

Teva announced new IMPACT-TD Registry data showing substantial burden from tardive dyskinesia (TD) in adults with mood disorders. According to Teva, most participants reported moderate to severe impact, with notable diagnostic gaps across age groups, especially in younger adults.

How many patients are included in Teva's IMPACT-TD Registry for tardive dyskinesia (TEVA)?

The IMPACT-TD Registry evaluates 611 adults aged 18 and older with tardive dyskinesia. According to Teva, this 3-year, prospective, non-interventional Phase 4 study examines TD progression and impact using broad real-world representation across age, sex, race, underlying conditions, and treatment status.

What does the Teva IMPACT-TD analysis show about young adults 18-29 with TD and mood disorders (TEVA)?

Among adults 18-29 with mood disorders and TD movements (n=13), 85% had moderate to severe global impact. According to Teva, only 23% received a formal TD diagnosis, indicating underdiagnosis despite considerable daily life and psychological effects in this age group.

How long do patients with mood disorders and tardive dyskinesia wait for diagnosis in Teva’s IMPACT-TD study?

Patients waited on average more than 3.5 years from first recognized involuntary movements to TD diagnosis. According to Teva, this delay highlights a substantial diagnostic gap for adults with mood disorders living with tardive dyskinesia symptoms in real-world settings.

How do TD diagnosis rates vary by age in Teva’s IMPACT-TD Registry (TEVA)?

Formal TD diagnosis rates were lowest in adults under 40, at 23% for ages 18-29 and 35% for 30-39. According to Teva, rates peaked at 57% for ages 40-49 and averaged 47% in adults 50 and older.

What psychological impact from tardive dyskinesia was observed in adults under 60 in Teva’s IMPACT-TD data?

Psychological impact was most pronounced in adults under 60, with 77% of those aged 18-29 experiencing moderate to severe psychological effects. According to Teva, these younger adults had lower AIMS severity scores than older groups but still reported high emotional burden.